Skip to main content

Table 2 Clinical trial populations included in analyses

From: Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials

AnalysisClinical Trials
Phase 3 DB
Phase 3 DB
Phase 3
DB and OL
Phase 2 DB
Phase 2 DB
Phase 3 OL
PharmacokineticaXXX XX
Baseline comparisonXXX   
Efficacy outcomesXXXb   
Safety outcomes
 Phase 3_PooledXXXb   
 All GMB ExposureXXXXXX
  1. Abbreviations: All GMB Exposure Patients treated with any GMB dose in any duration, DB Double blind, GMB Galcanezumab, OL Open label, Phase 3_Pooled, all patients from the 3 placebo-controlled phase 3 trials
  2. aIncludes results from phase 2 and 3 studies with 28-day or monthly dosing regimens
  3. bIncludes results from DB phase of trials only